139 related articles for article (PubMed ID: 17168656)
1. Targeting signaling pathways in multiple myeloma.
Federica C; Antonio P; Guido T; Mario B
Curr Pharm Biotechnol; 2006 Dec; 7(6):407-13. PubMed ID: 17168656
[TBL] [Abstract][Full Text] [Related]
2. Farnesyltransferase inhibitors and rapamycin in the treatment of multiple myeloma.
Zangari M; Cavallo F; Tricot G
Curr Pharm Biotechnol; 2006 Dec; 7(6):449-53. PubMed ID: 17168661
[TBL] [Abstract][Full Text] [Related]
3. Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma.
Podar K; Richardson PG; Chauhan D; Anderson KC
Expert Rev Anticancer Ther; 2007 Apr; 7(4):551-66. PubMed ID: 17428175
[TBL] [Abstract][Full Text] [Related]
4. Targeting pathways mediating bone disease.
Giuliani N; Morandi F; Tagliaferri S; Rizzoli V
Curr Pharm Biotechnol; 2006 Dec; 7(6):423-9. PubMed ID: 17168658
[TBL] [Abstract][Full Text] [Related]
5. Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma.
Anreddy N; Hazlehurst LA
J Cell Biochem; 2017 Jan; 118(1):15-25. PubMed ID: 27261328
[TBL] [Abstract][Full Text] [Related]
6. Targeting signalling pathways for the treatment of multiple myeloma.
Podar K; Hideshima T; Chauhan D; Anderson KC
Expert Opin Ther Targets; 2005 Apr; 9(2):359-81. PubMed ID: 15934921
[TBL] [Abstract][Full Text] [Related]
7. The Role of Intracellular Signaling Pathways in the Pathogenesis of Multiple Myeloma and Novel Therapeutic Approaches.
Kizaki M; Tabayashi T
J Clin Exp Hematop; 2016; 56(1):20-7. PubMed ID: 27334854
[TBL] [Abstract][Full Text] [Related]
8. Signaling Pathways and Emerging Therapies in Multiple Myeloma.
Ramakrishnan V; D'Souza A
Curr Hematol Malig Rep; 2016 Apr; 11(2):156-64. PubMed ID: 26922744
[TBL] [Abstract][Full Text] [Related]
9. Establishment of stable multiple myeloma cell line with overexpressed PDCD5 and its proapoptosis mechanism.
Feng W; Fu Y; Zhang Y; Lv B; Li X; Zhang F; Gui R; Liu J
Int J Clin Exp Pathol; 2015; 8(9):10635-43. PubMed ID: 26617773
[TBL] [Abstract][Full Text] [Related]
10. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
[TBL] [Abstract][Full Text] [Related]
11. Towards a new age in the treatment of multiple myeloma.
Piazza FA; Gurrieri C; Trentin L; Semenzato G
Ann Hematol; 2007 Mar; 86(3):159-72. PubMed ID: 17205287
[TBL] [Abstract][Full Text] [Related]
12. Growth factors and antiapoptotic signaling pathways in multiple myeloma.
van de Donk NW; Lokhorst HM; Bloem AC
Leukemia; 2005 Dec; 19(12):2177-85. PubMed ID: 16239913
[TBL] [Abstract][Full Text] [Related]
13. Various Signaling Pathways in Multiple Myeloma Cells and Effects of Treatment on These Pathways.
Dehghanifard A; Kaviani S; Abroun S; Mehdizadeh M; Saiedi S; Maali A; Ghaffari S; Azad M
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):311-320. PubMed ID: 29606369
[TBL] [Abstract][Full Text] [Related]
14. Apoptosis in multiple myeloma: therapeutic implications.
Chauhan D; Anderson KC
Apoptosis; 2001; 6(1-2):47-55. PubMed ID: 11321040
[TBL] [Abstract][Full Text] [Related]
15. Targeting SDF-1 in multiple myeloma tumor microenvironment.
Bouyssou JM; Ghobrial IM; Roccaro AM
Cancer Lett; 2016 Sep; 380(1):315-8. PubMed ID: 26655999
[TBL] [Abstract][Full Text] [Related]
16. The role of bone morphogenetic proteins in myeloma cell survival.
Holien T; Sundan A
Cytokine Growth Factor Rev; 2014 Jun; 25(3):343-50. PubMed ID: 24853340
[TBL] [Abstract][Full Text] [Related]
17. Apoptotic signaling in multiple myeloma: therapeutic implications.
Chauhan D; Hideshima T; Anderson KC
Int J Hematol; 2003 Aug; 78(2):114-20. PubMed ID: 12953804
[TBL] [Abstract][Full Text] [Related]
18. Melphalan-induced apoptosis in multiple myeloma cells is associated with a cleavage of Mcl-1 and Bim and a decrease in the Mcl-1/Bim complex.
Gomez-Bougie P; Oliver L; Le Gouill S; Bataille R; Amiot M
Oncogene; 2005 Dec; 24(54):8076-9. PubMed ID: 16091744
[TBL] [Abstract][Full Text] [Related]
19. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
[TBL] [Abstract][Full Text] [Related]
20. Curcumin ameliorates the in vitro efficacy of carfilzomib in human multiple myeloma U266 cells targeting p53 and NF-κB pathways.
Allegra A; Speciale A; Molonia MS; Guglielmo L; Musolino C; Ferlazzo G; Costa G; Saija A; Cimino F
Toxicol In Vitro; 2018 Mar; 47():186-194. PubMed ID: 29223572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
